Preoxygenation With Optiflow™ in Morbidly Obese Patients is Superior to Face Mask

• Status: Withdrawn
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Optiflow™ may provide an opportunity to prolong apnea time in the morbidly obese patient population. This study will examine whether Optiflow can do this, and compare the pre-oxygenation with Optiflow to the pre-oxygenation achieved with face mask.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Montefiore Medical Center
• Collaborators: M.D. Anderson Cancer Center; The University of Texas Health Science Center, Houston
• Treatments: Fentanyl; Midazolam; Propofol; Rocuronium

Criteria

Inclusion Criteria:

• Adult patients (≥ 18 years old) undergoing elective surgery requiring general anesthesia

• BMI > 40 kg/m2

• American Society of Anesthesiology (ASA) Physical Status II-III

Exclusion Criteria:

• Chronic hypoxemia (SpO2 <94% on room air or on home oxygen)

• Acute respiratory failure

• Coronary artery disease and/or congestive heart failure

• Moderate-Severe pulmonary hypertension and/or RV dysfunction

• Full stomach (recently eaten)

• Pregnancy

• Chronic pulmonary disease (specifically COPD or interstitial disease, NOT asthma)

• Respiratory tract pathology

• Facial Abnormality

• American Society of Anesthesiology (ASA) Physical Status IV-V